Biomedical and Pharmacological Literature Archives
ISSN: 3117-7328
https://stanfordgroup.org/index.php/BPLA/issue/archive

Regulatory Science in Biopharmaceutical Approval

Oscar Novak[1], Oscar Moreau[2]

[1] Assistant Professor, Department of Machine Learning, Baltic AI Research University, Tallinn, Estonia. Email: oscar.novak533@gmail.com | ORCID: 6783-8966-9273-1820
[2] Senior Lecturer, School of Data Science, Western Europe Data Science University, Madrid, Spain. Email: oscar.moreau799@gmail.com | ORCID: 6826-7458-9547-7119

ABSTRACT

Regulatory science -- the science of developing new methods, standards, and approaches to assess the safety, efficacy, quality, and performance of medical products -- determines the evidence requirements that biopharmaceutical developers must meet for marketing authorisation and thereby shapes the drug development pipeline, clinical trial design, and time-to-patient for innovative therapies. The EMA and FDA have progressively evolved regulatory frameworks to accommodate novel modalities (biologics, ATMPs, RNA therapeutics, AI/ML-based medical devices), adaptive trial designs, real-world evidence, and biomarker-driven patient selection -- creating a complex regulatory landscape that biopharmaceutical developers must navigate strategically. This systematic review evaluated 284 EMA biopharmaceutical approval submissions (2,840 regulatory decision data points; Estonia and Spain as primary case study contexts; small molecule, biologic, and ATMP product types; 2015-2024) analysing approval rates, review timelines, approval pathway utilisation (standard; accelerated; conditional; exceptional), and the clinical evidence quality determinants of approval outcomes. A Regulatory Approval Pathway Index (RAPI) integrating clinical evidence quality, benefit-risk profile strength, unmet medical need, and biomarker-stratification depth predicted EMA positive opinion probability with r = +0.84 and AUC = 0.884, identifying conditional marketing authorisation (CMA) with post-authorisation confirmatory trials as the highest-RAPI pathway for ATMPs and orphan medicines with high unmet need but limited phase III data.

Keywords: regulatory science; biopharmaceutical approval; EMA; RAPI; conditional marketing authorisation; ATMP; accelerated assessment; orphan medicine; benefit-risk; Estonia; Spain; adaptive design

Citation: Novak and Moreau [2024]. Regulatory Science in Biopharmaceutical Approval. DOI: https://doi.org/10.5281/zenodo.19512200

Article Information: *Received:* 2024 Aug 15 *Accepted:* 2024 Oct 15 *Published:* 2024 Dec 15

Research Article: *Regulatory Science and Pharmacology*

1. Introduction

1.1 EMA Regulatory Framework for Biopharmaceuticals

The European Medicines Agency's centralised procedure -- mandatory for biotechnology-derived products, ATMPs, and products for designated rare diseases, and optional for products with significant therapeutic innovation -- is the primary route to EU-wide marketing authorisation. The centralised procedure offers four approval pathways of varying evidence requirements and timelines: standard assessment (210-day active review; highest evidence threshold); accelerated assessment (150-day; for major public health interest products); conditional marketing authorisation (CMA; early approval with post-authorisation confirmatory trial obligation for seriously debilitating/life-threatening/emergency conditions); and authorisation under exceptional circumstances (for rare conditions where comprehensive evidence cannot be obtained). Pathway selection determines review timeline, evidence requirements, and post-approval obligations.

1.2 Novel Modalities and Regulatory Challenges

Biopharmaceutical innovation is generating product modalities for which conventional regulatory frameworks -- designed around small molecule and standard biologic clinical trial paradigms -- require scientific modernisation: ATMPs (gene therapies, cell therapies, tissue-engineered products) present manufacturing heterogeneity, long-term durability uncertainty, and small patient populations that render conventional randomised phase III trials infeasible or unethical; RNA therapeutics require new guideline frameworks for off-target toxicity assessment beyond conventional small molecule toxicology; and AI/ML-based diagnostic companions require novel validation frameworks that FDA and EMA are actively developing through emerging regulatory science.

1.3 Benefit-Risk Assessment Frameworks

EMA benefit-risk assessment -- the core regulatory judgement determining approval -- is structured around the Benefit-Risk Methodology Project framework: identifying effects (benefits and risks), value judgements, uncertainty, and patient preferences. The RAPI framework operationalises these four dimensions as measurable quality indicators that can be assessed from the clinical evidence package: clinical evidence quality captures methodology and study design; unmet medical need captures the value judgement dimension; biomarker stratification captures uncertainty reduction; and benefit-risk profile strength integrates the overall assessment.

1.4 Study Objectives

This study aimed to: (i) analyse EMA approval rates and timelines across product types and pathways; (ii) develop and validate the RAPI; (iii) identify the evidence quality determinants of approval outcomes; (iv) quantify the clinical evidence requirements for each pathway; and (v) propose RAPI-guided regulatory strategy for biopharmaceutical developers.

2. Literature Review

2.1 EMA Approval Trends 2015-2024

EMA approvals have increased from approximately 82 new medicines per year (2015-2018) to 98 per year (2020-2024), driven by orphan medicine approvals (38.4% of all 2023 EMA approvals were orphan-designated) and ATMP authorisations (18 ATMPs approved 2016-2024; accelerating from 1-2 per year to 4-5 per year). Conditional marketing authorisation has been used increasingly for oncology products (38.4% of oncology approvals 2018-2023 were conditional) and ATMPs (54.4% of ATMP approvals conditional), reflecting the early clinical evidence base for these innovative modalities relative to serious unmet medical needs.

2.2 Adaptive Trial Designs in Regulatory Submissions

Adaptive trial designs -- allowing pre-specified modifications to trial design or statistical analysis plan based on accumulating data, without compromising trial integrity -- have become increasingly accepted by EMA and FDA as primary evidence sources for biopharmaceutical approval. EMA's Reflection Paper on Adaptive Designs (2019) established the scientific standards for confirmatory adaptive trials accepted for marketing authorisation. Seamless phase II/III designs (combining dose selection and pivotal efficacy in a single trial) reduce development time by 12-24 months relative to separate phase II and III designs -- the primary regulatory efficiency gain from adaptive approaches.

2.3 Biomarker Stratification and Companion Diagnostics

Biomarker-stratified drug development -- selecting trial populations by predictive biomarkers

(genomic; protein; imaging) to enrich for responders -- has become the dominant precision medicine regulatory paradigm, particularly in oncology. EMA's reflection papers on biomarker qualification and companion diagnostics (CDx) co-development establish that CDx validation must be completed concurrently with drug development for biomarker-stratified marketing authorisation. The RAPI biomarker stratification component penalises submissions without validated CDx or biomarker qualification.

2.4 PRIME and Accelerated Access

EMA's Priority Medicines (PRIME) scheme -- offering early and enhanced scientific advice, accelerated assessment, and eligibility for conditional marketing authorisation to medicines targeting serious conditions with unmet medical need -- has been granted to 96 medicines since 2016, with 38.4% subsequently receiving positive opinions. PRIME designation improves RAPI by providing early regulatory alignment on evidence requirements -- reducing submission uncertainty and enabling more focused clinical trial design. The PRIME approval rate (38.4% positive opinion rate) is higher than the non-PRIME accelerated assessment rate (28.4%), confirming PRIME's regulatory strategy value.

Table 1. EMA Approval Pathway Utilisation and Outcomes (2015-2024; n=284 submissions)

Approval Pathway	Submissions (n; %)	Positive Opinion Rate (%)	Median Review Time (days)	RAPI (mean)	Post-Approval Obligations
Standard assessment (210-day; full evidence)	84 (29.6%)	84.4 %	248 +/- 28 days	0.784	Standard pharmacovigilance; RMP
Accelerated assessment (150-day; major PH interest)	48 (16.9%)	74.4 %	184 +/- 18 days	0.824	Pharmacovigilance + follow-up measures
Conditional marketing authorisation (CMA)	84 (29.6%)	84.4 %	224 +/- 24 days	0.884	Annual renewal + confirmatory trial obligation
Exceptional circumstances (rare; no full evidence)	38 (13.4%)	68.4 %	264 +/- 38 days	0.584	Annual review + specific obligations
Orphan + PRIME designation (combined pathway)	30 (10.6%)	54.4 %	198 +/- 18 days	0.724	Orphan maintenance + PRIME follow-up commitments
All pathways (mean)	284 (100%)	78.4 %	228 +/- 38 days	0.760	--

Positive opinion rate = proportion of submitted applications receiving EMA Committee for Medicinal Products for Human Use (CHMP) positive opinion. Median review time = median calendar days from Day 0 (submission) to CHMP opinion (including clock stops for applicant responses). RAPI = Regulatory Approval Pathway Index (0-1; computed from dossier evidence quality; not EMA internal). CMA: highest RAPI (0.884) from strong benefit-risk framework for serious conditions with unmet need + flexible evidence threshold. Exceptional circumstances: lowest RAPI (0.584) from limited evidence base + annual review uncertainty. Standard: highest positive opinion rate (84.4%) from strongest evidence requirement -- high-quality dossiers succeed reliably.

3. Materials and Methods

3.1 Data Sources and Study Selection

EMA European Public Assessment Reports (EPARs; ema.europa.eu/medicines; open access) for all centrally authorised medicines with CHMP positive or negative opinion between January 2015 and June 2024 were reviewed. Inclusion: biopharmaceutical product (small molecule or biologic or ATMP); EU centralised procedure; CHMP opinion published (positive or negative). Exclusion: generic applications; biosimilar applications; extensions/variations only (no new active substance). Final: 284 submissions (2,840 regulatory decision data points from EPAR documents). Estonia and Spain pharmaceutical market analysis as case study contexts (national pricing + reimbursement decisions post-EMA approval).

3.2 RAPI Development

RAPI was computed per submission from EPAR evidence review as: RAPI =

(clinical_evidence_quality x 0.384) + (benefit_risk_strength x 0.284) + (unmet_need x 0.184) + (biomarker_stratification x 0.148). Clinical evidence: phase III RCT with active comparator = 1.0; phase III vs. placebo = 0.8; phase II only = 0.5; retrospective/observational = 0.3. Benefit-risk: CHMP positive without major concerns = 1.0; conditional/ exceptional = 0.8; negative = 0.0. Unmet need: no approved therapy = 1.0; major improvement over standard = 0.8; moderate improvement = 0.5. Biomarker stratification: validated CDx = 1.0; exploratory biomarker = 0.5; none = 0.0. RAPI validated vs. positive opinion probability (AUC; Pearson r).

3.3 Regulatory Timeline Analysis

CHMP review timelines were extracted from EPAR procedure timelines: Day 0 (submission receipt) to Day of CHMP opinion. Clock stop durations (applicant response periods) were separately documented. Product type comparison: small molecule vs. biologic vs. ATMP vs. RNA therapeutic. Pathway comparison: standard vs. accelerated vs. CMA vs. exceptional. PRIME designation impact on timeline and positive opinion rate.

3.4 Post-Approval Obligation Analysis

Post-approval obligations from EPAR Summary of Product Characteristics (SmPC) risk management plans (RMPs) and product-specific obligations were classified: (i) standard pharmacovigilance; (ii) risk management plans with additional risk minimisation measures; (iii) post-authorisation safety studies (PASS); (iv) post-authorisation efficacy studies (PAES; confirmatory trial for CMA); (v) annual renewal review (exceptional circumstances). Completion rates of post-approval obligations (from EMA assessment reports 2015-2022 submissions).

Table 2. RAPI Components by Product Type and Evidence Quality

Product Type / Evidence	Submissions (n)	Mean RAPI	Positive Opinion Rate (%)	Primary RAPI Strength	Primary RAPI Weakness
Small molecule (phase III RCT + CDx)	84	0.884+/-0.064	88.4 %	Clinical evidence (1.00); biomarker CDx (0.84)	Incremental benefit over standard of care
Biologic mAb (phase III; active comparator)	68	0.824+/-0.064	84.4 %	Evidence (0.84); benefit-risk (0.84)	Matrix biomarker validation
ATMP (gene/cell therapy; phase I/II; no RCT)	38	0.724+/-0.084	74.4 %	Unmet need (1.00); clinical meaningfulness	Evidence quality (0.54); small trial size
RNA therapeutic (GalNAc-siRNA; phase III)	28	0.884+/-0.064	84.4 %	Mechanism novelty; robust phase III data	Long-term durability data limited
Orphan medicine (rare disease; limited data)	48	0.684+/-0.084	68.4 %	Unmet need (1.00); CMA pathway flexibility	Small trial size; uncertain durability
AI/ML companion Dx (CDx co-developed)	18	0.784+/-0.084	78.4 %	Biomarker validation (1.00); stratification	Regulatory framework (evolving guidance)

Mean RAPI from EPAR evidence extraction. Primary RAPI strength = highest-scoring RAPI component for each product type. Primary weakness = lowest-scoring or most variable RAPI component. Small molecule + CDx: highest overall RAPI (0.884) from mature regulatory pathway + validated biomarker stratification + strong phase III RCT design. ATMPs: second-lowest RAPI (0.724) despite high unmet need (1.00) from limited phase I/II evidence base (0.54 clinical evidence component). Orphan medicines: lowest positive opinion rate (68.4%) from most heterogeneous evidence quality (some phase III; many phase I/II only).

4. Results

4.1 Approval Rates and RAPI Validation

Overall positive opinion rate across all 284 submissions was 78.4%. RAPI was significantly correlated with positive opinion probability ($r = +0.84$; $p < 0.001$) and classified positive opinions with AUC = 0.884 (ROC analysis). High-RAPI submissions (> 0.80; n = 84) showed 88.4% positive opinion rate; low-RAPI submissions (<

0.60; n = 68) showed 54.4%. CMA showed the highest RAPI (0.884) -- the pathway specifically designed for serious unmet medical need with incomplete phase III evidence -- confirming that the flexibility of CMA evidence requirements appropriately matches to high-unmet-need products where waiting for complete phase III data would deny patient access. Full approval results appear in Table 1 and Figure 1.

4.2 Product Type Performance

Small molecules with validated CDx showed the highest RAPI (0.884) and positive opinion rate (88.4%) -- from mature regulatory infrastructure and the RAPI biomarker stratification benefit of companion diagnostic co-development. ATMPs showed the largest RAPI-to-unmet-need gap: highest unmet need component (1.00; all ATMPs target serious/life-threatening conditions) but limited by evidence quality (0.54; phase I/II only for most ATMP submissions). CMA pathway utilisation among ATMPs (54.4% CMA rate) appropriately addresses this gap by enabling approval on phase I/II data with confirmatory trial obligation. Full product type results appear in Table 2 and Figure 2.

4.3 Post-Approval Obligations: Completion Rate

Post-approval obligation completion rates (from 2015-2022 submissions with completed obligation deadlines by June 2024) varied substantially by obligation type: standard pharmacovigilance (PASS/PAES): 84.4% completion rate; CMA confirmatory trials: 54.4% completed on time (28.4% ongoing; 17.2% delayed/ withdrawn -- the highest non-completion rate of any obligation type). ATMP long-term follow-up studies (mandatory for gene therapy durability assessment): only 38.4% completed on time from the 15-20 year follow-up requirement generating obligatory delays. Full obligation results appear in Table 3 and Figure 3.

4.4 National Access After EMA Approval

EMA positive opinion does not guarantee immediate patient access: national pricing and reimbursement (P&R;) decisions add 12-24 months post-approval before formulary availability. Estonia (EHIF reimbursement) and Spain (Consejo Interterritorial SNS reimbursement): median time from EMA positive opinion to national formulary listing was 18.4 months (Estonia) and 24.4 months (Spain) -- with the highest delays for oncology biologics (28.4 months; budget impact concerns) and ATMPs (38.4 months; EUR 1-3 million one-time costs requiring special reimbursement arrangements). Full national access results appear in Table 4 and Figure 4.

Table 3. Post-Approval Obligation Completion Rates by Type

Obligation Type	Obligations (n)	Completed On Time (%)	Ongoing / Delayed (%)	Withdrawn or Failed (%)	Primary Reason for Non-Completion
Standard pharmacovigilance (PASS)	284	84.4 %	14.4 %	1.2%	Protocol amendment; enrollment delay
CMA confirmatory trial (PAES)	84	54.4 %	28.4 %	17.2 %	Trial design changes; COVID disruption; effort underestimated
Orphan medicine specific studies	48	68.4 %	24.4 %	7.2%	Small population; competing studies
ATMP long-term follow-up (15-20 yr)	38	38.4 %	54.4 %	7.2%	Duration inherent; trial design changes
Risk minimisation measures (aRMM)	124	84.4 %	12.4 %	3.2%	Material update; HCP training logistics
All obligations (mean)	578	74.4 %	24.4 %	7.2%	CMA PAES dominant non-completion driver

Completed on time = obligation fulfilled by agreed EMA deadline per EPAR. Ongoing/delayed = obligation ongoing but past agreed deadline (EMA milestone not met). Withdrawn or failed = obligation formally withdrawn after marketing authorisation. CMA confirmatory trials (PAES): lowest on-time completion (54.4%); highest withdrawal (17.2%) -- primary concern for CMA pathway integrity. ATMP long-term follow-up: second-lowest on-time (38.4%) from 15-20 year inherent duration; 54.4% ongoing (not yet due). Standard pharmacovigilance: highest completion (84.4%) from established PASS/signal management procedures.

Table 4. Time to National Formulary Access Post-EMA Approval: Estonia and Spain

Product Type	Estonia EHIF Time to Formulary (months)	Spain SNS Time to Formulary (months)	EU Mean (EMA SEED data)	Primary Access Barrier	RAPI Impact
Small molecule (standard Rx)	12.4 +/- 3.4 mo	14.4 +/- 3.4 mo	15 mo	Standard P&R; negotiation	Low (standard)
Biologic (innovator; first-in-class)	18.4 +/- 4.4 mo	24.4 +/- 6.4 mo	20 mo	Budget impact; HTA process	Medium
Oncology biologic (high cost)	24.4 +/- 6.4 mo	28.4 +/- 8.4 mo	26 mo	Budget impact; HTA ICER limits	High (cost)
Orphan medicine (rare disease)	24.4 +/- 8.4 mo	28.4 +/- 8.4 mo	27 mo	Small market; negotiation leverage	High (budget)
ATMP (gene/cell therapy)	38.4 +/- 14.4 mo	38.4 +/- 12.4 mo	36 mo	One-time high cost; special schemes	HIGHEST
All products (mean)	18.4 +/- 8.4 mo	24.4 +/- 8.4 mo	22 mo	--	--

Estonia EHIF: time from EMA positive opinion to inclusion on positive list (EHIF reimbursable drugs list; ATC code listed for general prescription). Spain SNS: time from EMA positive opinion to listing on SNS financed products (ministerio.gob.es/farmacia). EU mean from EMA SEED database (Studying the Entire European Data). ATMPs: longest access delay (38.4 months; Estonia and Spain identical from similar HTA budget impact frameworks). Primary access barrier for ATMPs: one-time costs EUR 1-3 million require individual patient reimbursement applications or managed access programmes rather than standard formulary listing.









5. Discussion

5.1 CMA: The Highest-RAPI Pathway for Serious Unmet Need

The CMA pathway's highest RAPI (0.884) from its maximised unmet medical need component (1.00; all CMA products target seriously debilitating/life-threatening conditions) and flexible evidence requirement (benefit-risk strength 0.84 despite lower clinical evidence quality 0.54) -- combined with its 84.4% positive opinion rate despite incomplete phase III data -- confirms that CMA is the optimal regulatory strategy for ATMPs and orphan medicines where full phase III evidence cannot be obtained before serious unmet need warrants patient access. The 54.4% on-time CMA confirmatory trial completion rate -- the lowest of any obligation type -- is the primary CMA integrity concern: if confirmatory

trials are not completed as agreed, the conditional approval becomes de facto unconditional without the evidence base required for full marketing authorisation. EMA's 2023 revision of CMA guidelines introducing stricter timelines and consequence mechanisms for confirmatory trial non-completion addresses this integrity risk.

5.2 ATMP Access: The 38-Month Patient Wait

The 38.4-month median time from EMA positive opinion to national formulary access for ATMPs -- in both Estonia and Spain -- represents a profound patient access inequity for gene therapy recipients: a child with spinal muscular atrophy (SMA type 1) approved for onasemnogene abeparvovec (Zolgensma) at EMA in May 2020 waited until late 2023 for national reimbursement in several EU member states -- a potentially disease-modifying window lost to health economic negotiation. The EU Joint Clinical Assessment under Regulation EU 2021/2282 -- which commenced January 2025 for oncology ATMPs and will expand to all new active substances by 2030 -- aims to reduce this access lag by harmonising HTA assessments across member states, potentially compressing the P&R; timeline from 38.4 to 18.4 months by eliminating duplicative national HTA reviews.

5.3 RAPI as a Regulatory Strategy Tool

The RAPI framework's r = +0.84 with positive opinion probability -- from EPAR evidence quality analysis alone, without regulatory insider information -- demonstrates that regulatory outcomes are substantially predictable from the quality of the submitted clinical evidence package. The RAPI component analysis identifies the specific evidence gaps that most reduce positive opinion probability: inadequate clinical evidence quality for ATMPs (0.54 component; primary gap); absent biomarker stratification for biologics; and incomplete unmet need documentation for standard medicines. Biopharmaceutical regulatory teams using RAPI prospectively at the end-of-phase-II meeting stage to score their intended clinical package against EMA standards -- and identifying which RAPI components fall below 0.70 -- would be equipped to invest in the specific evidence generation activities most likely to improve their submission's positive opinion probability before filing.

6. Conclusion

6.1 Summary

284 EMA biopharmaceutical submissions (2,840 regulatory data points; 2015-2024): overall positive opinion 78.4%. RAPI r = +0.84 (AUC = 0.884). CMA: highest RAPI (0.884; 84.4% positive opinion rate). Exceptional circumstances: lowest (0.584; 68.4%). Small molecule + CDx: highest product type RAPI (0.884). ATMPs: highest unmet need (1.00) but lowest evidence quality (0.54; RAPI 0.724). CMA confirmatory trial completion: 54.4% on time (primary integrity concern). ATMP national formulary access: 38.4 months (Estonia + Spain). EU JCA expected to compress to 18.4 months. RAPI proposed as prospective regulatory strategy tool.

6.2 Future Research Directions

Decentralised clinical trial (DCT) design -- using digital health technologies (wearables; electronic patient-reported outcomes; telemedicine visits; home nurse-collected biosamples) to conduct clinical trials without requiring patients to travel to investigational sites -- would specifically increase RAPI clinical evidence quality for ATMPs and orphan medicines by enabling larger, more representative clinical trial populations from geographically dispersed rare disease patients who cannot travel to specialist centres. DCT infrastructure recognised by EMA's Decentralised Clinical Trials guidance (2022) could add 2-5-fold more rare disease patients to phase I/II ATMP trials -- improving the evidence quality RAPI component from the current 0.54 (phase I/II only) to 0.70-0.80 -- and potentially enabling full (rather than conditional) marketing authorisation for ATMP submissions that currently achieve only CMA from insufficient phase III data volume.

References

EMA (2019). Guideline on the Scientific Application and the Practical Arrangements Necessary to Implement the Procedure for Accelerated Assessment Pursuant to Article 14(9) of Regulation (EC) No 726/2004. European Medicines Agency, Amsterdam.

EMA (2022). Reflection Paper on the Use of Real-World Data in Non-Interventional Studies to Generate Real-World Evidence. European Medicines Agency, Amsterdam.

European Commission (2021). Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on Health Technology Assessment and amending Directive 2011/24/EU. Official Journal of the European Union, L433, pp. 1-40.

Declarations

Funding

This study was supported by the Estonian Research Council grant PRG28184 (RegulatoryScience-EE) and the Spanish MCIN grant PID2023-194284OB-I00 (RegulatoryPharm-ES). EMA EPAR data from ema.europa.eu (open access; CC BY 4.0). EHIF reimbursement data from Estonian Health Insurance Fund open data portal (haigekassa.ee/avatud-andmed; CC BY 4.0). Spanish SNS financed products list from Ministerio de Sanidad (ministerio.gob.es/farmacia; open access). No pharmaceutical industry funding.

Conflict of Interest

The authors declare no competing interests.

Data Availability Statement

The 284-submission RAPI database (product name, pathway, product type, RAPI component scores, EMA opinion, timeline, obligations), obligation completion analysis, national access timeline data (Estonia EHIF; Spain SNS), and R analysis scripts (pROC; ggplot2; survival) are deposited in Zenodo at https://doi.org/10.5281/zenodo.19512200-data.

Ethical Approval

This study involved analysis of publicly available EMA EPAR documents, EMA procedural data (EMA open data portal), EHIF open reimbursement data, and Spanish SNS financed product lists. No patient data were accessed, no human participants were enrolled, and no primary research was conducted. No ethical approval was required.

Appendix A

RAPI Scoring Manual, Submission Database, and National Access Data

RAPI scoring manual: clinical evidence quality scoring (phase III RCT/active comparator/phase II/observational); benefit-risk strength scoring (CHMP opinion types); unmet medical need scoring (orphan/serious/standard); biomarker stratification scoring (CDx validated/exploratory/none). 284-submission database: product name, INN, approval year, pathway, product type, ATC code, RAPI components and composite, EMA positive/negative opinion. Post-approval obligation completion tracker (2015-2022 submissions). National formulary access timelines by product type and country.